Clinical Policy: Cabazitaxel (Jevtana)

Reference Number: LA.PHAR.316
Effective Date: 11.03.23
Last Review Date: 06.11.24 ~~06.25.23~~
Line of Business: Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information. ~~n.~~

****Please note: This policy is for medical benefit****

Description
Cabazitaxel (Jevtana®) is a microtubule inhibitor.

FDA Approved Indication(s)
Jevtana is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with a docetaxel-containing treatment regimen.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that Jevtana is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Prostate Cancer (must meet all)**:**

1. Diagnosis of metastatic CRPC, as evidenced by disease progression despite bilateral orchiectomy or other androgen deprivation therapy (*see Appendix D*);
2. Prescribed by or in consultation with an oncologist or urologist;
3. Age ≥ 18 years;
4. Previously treated with a docetaxel-containing treatment regimen, unless member is not a candidate for or ~~are~~is intolerant of docetaxel;
5. At the time of request, member has none of the following contraindications:
   a. Neutrophil counts of ≤ 1,500/mm^3;
   b. Severe hepatic impairment (total bilirubin > 3 × upper limit of normal);
6. Jevtana is prescribed concurrently with corticosteroid (*see Appendix E*);
7. Member will use a gonadotropin-releasing hormone (GnRH) analog concurrently or has had a bilateral orchiectomy;
8. Requests meets one of the following (a or b~~): *~~):*
   a. Dose does not exceed 25 mg/m^2 once every 3 weeks;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Style Definition: Unresolved Mention
Formatted: Font: 24 pt
Deleted Cells
Formatted Table
Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, … + Start at: 1 + Alignment: Left + Aligned at: 0.5" + Indent at: 0.75"
Formatted: Indent: Left: 0.75", Numbered + Level: 2 + Numbering Style: a, b, c, … + Start at: 1 + Alignment: Left + Aligned at: 1.5" + Indent at: 1.75"
Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, … + Start at: 1 + Alignment: Left + Aligned at: 0.5" + Indent at: 0.75"
Formatted: Indent: Left: 0.75", Numbered + Level: 2 + Numbering Style: a, b, c, … + Start at: 1 + Alignment: Left + Aligned at: 1.5" + Indent at: 1.75"

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2)**:**

~~1.~~ 1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255

~~2.~~ 2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53

II. Continued Therapy

A. Prostate Cancer (must meet all)**:**

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Jevtana for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Jevtana is prescribed concurrently with corticosteroid (*see Appendix E*);
4. Member continues to use a gonadotropin-releasing hormone (GnRH) analog concurrently or has had a bilateral orchiectomy;
5. If request is for a dose increase, request meets one of the following (a or b):*
   a. ~~a.~~ New dose does not exceed 25 mg/m^2 once every 3 weeks;
   b. ~~b.~~ New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

   **Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
CRPC: castration resistant prostate cancer

Formatted: Indent: Left: 0.25", Keep with next
Formatted: Normal, Indent: Left: 1", No bullets or numbering, Pattern: Clear (Background 1)
Formatted: Font color: Auto
Formatted: Font color: Text 1
Formatted: Font color: Auto
Formatted: Font: Not Bold, Font color: Auto
Formatted: Font color: Black
Formatted: Indent: Left: 0.75", Numbered + Level: 2 + Numbering Style: a, b, c, … + Start at: 1 + Alignment: Left + Aligned at: 1" + Indent at: 1.25"
Formatted: Superscript
Formatted: Font color: Black
Formatted: Font color: Black
Formatted: Font: Italic
Formatted: Font color: Black

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent ~~for all relevant lines of business~~ and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
docetaxel	Androgen-deprivation therapy with docetaxel 75 mg/m^2 for 6 cycles	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s):
  - Neutrophil counts of ≤ 1,500/mm^3
  - History of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80
  - Severe hepatic impairment (total bilirubin > 3x upper limit of normal)
- Boxed warning(s): neutropenia and hypersensitivity

Appendix D: General Information
- CRPC is prostate cancer that progresses clinically, radiographically, or biochemically despite castrate levels of serum testosterone (< 50 ng/dL). Per the NCCN, androgen deprivation therapy should be continued in the setting of CRPC while additional therapies are applied.
- Examples of androgen deprivation therapy include:
  - Bilateral orchiectomy (surgical castration)
  - Luteinizing hormone-releasing hormone (LHRH) given with or without an ~~antiandrogen~~anti-androgen:
    - LHRH agonists: Zoladex® (goserelin), ~~Vantas® (histrelin),~~ leuprolide (Lupron Depot®, Eligard®), and Trelstar® (triptorelin)
    - Anti-androgens: bicalutamide (Casodex®), flutamide (Eulexin®), nilutamide (Nilandron®), Xtandi® (enzalutamide), Erleada® (apalutamide), Nubeqa® (darolutamide)
  - LHRH ~~antagonist~~antagonists: Firmagon® (degarelix), Orgovyx™ (relugolix)

Appendix E: Concurrent Steroid Therapies
- Dexamethasone on the day of chemotherapy
- Prednisone daily

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CRPC	20 ~~or 25~~ mg/m^2 IV every 3 weeks	25 mg/m^2 once every 3 weeks

VI. Product Availability
Single-dose vial: 60 mg/1.5 mL~~, 45 mg/4.5mL, 60mg/6mL~~

Formatted Table
Formatted Table
Formatted: Pattern: Clear (White)
Formatted: Pattern: Clear (White)
Formatted: Indent: Left: 0.25"
Formatted: Pattern: Clear (White)
Formatted: Font color: Purple
Formatted: Font color: Purple
Formatted: Indent: Left: 0.5"
Formatted: Font color: Purple
Formatted: Indent: Left: 0.5", Pattern: Clear
Formatted: Superscript
Formatted: Superscript
Formatted: Superscript
Formatted: Superscript
Formatted: Indent: Left: 0.75", Pattern: Clear
Formatted: Font color: Black

VII. References

1. Jevtana Prescribing Information. Bridgewater, NJ: Sanofi-Aventis US LLC; ~~February 2021.~~July 2023. Available at: https://www.jevtanapro.com/. Accessed January ~~26, 2023~~9, 2024.
2. Cabazitaxel Injection Prescribing Information. Princeton, NJ: Sandoz Inc.; January 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208715s000lbl.pdf. Accessed January ~~10, 2023~~9, 2024.
3. Cabazitaxel. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: ~~https://www.nccn.org/professionals/drug_compendium. Accessed January 10, 2023~~https://www.nccn.org/professionals/drug_compendium. Accessed January 9, 2024.
4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in ~~Ongcology~~Oncology: Prostate Cancer. Version ~~1~~4.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed January ~~10, 2023~~9, 2024.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9043	Injection, cabazitaxel, 1 mg
J9064	Injection, cabazitaxel (sandoz), not therapeutically equivalent to J9043, 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	06.25.23	10.05.23
Annual review: no significant changes; removed 45 mg/4.5 mL strength from Section VI; Added HCPCS code [J9064]; references reviewed and updated	06.11.24	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developingthis clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

Formatted: Font color: Auto
Formatted: Font color: Auto
Formatted: Font color: Auto
Formatted: Font color: Auto
Formatted: Font color: Auto
Formatted: Font: Bold
Formatted Table
Formatted: Font: Not Bold, No underline
Formatted: Indent: Left: 0"

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.
This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Formatted: Indent: Left: 0", Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

Formatted: Indent: Left: 0"